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What is known about the subject?
 ► Maternal recurrent infections can have an important 
role in the occurrence of symptomatic infections.
 ► The registry of congenital cytomegalovirus (CMV) 
infections has been below those estimated by epi-
demiological studies.
What this study adds?
 ► The probability of congenital CMV infection being 
symptomatic at birth may be significantly higher for 
non-primary maternal infection in Portugal.
 ► Surveillance through European paediatric surveil-
lance units gave similar under-reporting results (in 
the current study, the prevalence rate was 6.6:105 
live births).
 ► There is a need for new strategies to improve the 
adherence of clinicians to the registry.
AbstrACt
Objective Human cytomegalovirus (CMV) is the most 
widespread agent of congenital infection in humans and 
is still a challenging issue. Despite lower rates of vertical 
transmission being associated with recurrent infection 
when compared with primary infection, the first still 
represents the majority of congenital infections worldwide. 
Based on data from active reporting, we explored the 
influence of maternal primary/non-primary infection 
both on the presentation and outcome of congenital CMV 
infection in early childhood.
Design Infants with positive viruria during the first 
3 weeks of life were reported through the Portuguese 
Paediatric Surveillance Unit.
Patients Infants born between 2006 and 2011 with 
confirmed congenital CMV infection.
Methods Maternal infection was considered primary 
if CMV IgG seroconversion occurred during pregnancy or 
low avidity IgG was documented; it was considered non-
primary if positive IgG was documented before pregnancy 
or high avidity CMV IgG was present early in pregnancy. 
Follow-up questionnaires were sent up to 6 years of age.
results Forty confirmed cases of congenital CMV 
infection were reported (6.6:105 live births, 95% CI 4.81 
to 8.92); 22 out of 40 were asymptomatic. The odds 
for non-primary maternal infection if the offspring was 
symptomatic at birth were 6.2 (95% CI 1.2 to 32.27).
Conclusion The reported number of confirmed cases of 
congenital CMV infection was much lower than expected. 
Under-reporting and missed diagnosis were considered 
possible reasons. Non-primary maternal infections were 
associated with symptomatic congenital CMV infection 
in the offspring. Maternal recurrent infections can have 
a significant impact on the total number of symptomatic 
infections in Portugal.
IntrODuCtIOn
Human cytomegalovirus (CMV) is the most 
widespread agent of congenital infection in 
humans. About 0.7% of all newborn infants 
around the world are congenitally infected by 
CMV, with rates varying from 0.2% to 2.2%, 
and of these 10%–15% will be born with 
symptoms. Among the infants who are born 
asymptomatic, about 10%–15% will develop 
late sequelae, such as neurological impair-
ment or neurosensorial hearing loss.1
After maternal primary infection, transmis-
sion to the fetus occurs in 30%–35% of cases, 
and clinical disease will be present in around 
10%–15% of those born with congenital 
infection. In women who are already seropos-
itive, reactivation may cause fetal infection, at 
a rate of about 1.2%.2 Although transmission 
in recurrent infection is much lower than in 
primary infection, it is the main contributor 
to the total number of congenital infections 
(and disease) worldwide. In addition, an 
increased number of observations demon-
strates that the risk for symptomatic infec-
tion at birth and sequelae after primary and 
non-primary maternal CMV infections, espe-
cially hearing loss, is not as different as previ-
ously assumed.3
Population surveillance systems for congen-
ital CMV infection, intended to register all 
confirmed cases, are crucial to evaluate the 
impact of this infection. Different approaches 
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for the registry of cases have been used, including 
national programmes and the search of databases on 
hospital records.4–7 Although under-reporting is common 
in these surveillance systems, valuable information can 
be obtained from the registry of congenital infections.
Between 2006 and 2011, an experimental surveillance 
of infants with congenital CMV infection was carried on 
through the Portuguese Paediatric Surveillance Unit 
(PPSU)8 in order to estimate the number of cases of 
congenital CMV infection in Portugal, the proportion 
of maternal primary/non-primary infections responsible 
for these cases, and the outcome of these children in 
early childhood.
MAterIAls AnD MethODs
Between 2006 and 2011, infants born in Portugal with 
confirmed congenital CMV infection (positive viruria 
during the first 3 weeks of life, detected by commercial 
PCR techniques or shell vial culture) were reported 
through the PPSU, a national surveillance programme 
ran through the Portuguese Paediatric Society. Clinicians 
were asked to complete questionnaires about clinical and 
laboratory presentations at birth, at 6, 12 and 18 months, 
and at 2, 3, 4, 5 and 6 years of age. Follow-up for the 
last reported children ended in 2017 (protocol available 
at http://www. spp. pt/ conteudos/ default. asp? ID= 143). 
The questionnaire at presentation (questionnaire in 
English in online supplementary file 1) included identi-
fication of the notifier and a coded identification of the 
patient; data on gestational age, birth weight and exams 
during gestation (serology, ultrasound scan and amni-
ocentesis result, if performed); viruria for CMV in the 
first 3 weeks of age; clinical symptoms (fever, sepsis-like 
syndrome, weight below the 10th percentile for gesta-
tional age and/or postnatal age, pneumonia, hepatosple-
nomegaly, microcephaly, and seizures); laboratory blood 
and cerebrospinal fluid findings (hepatitis, cholestasis, 
anaemia (haemoglobin <140 g/L in the first week or <12 
mg/dL in the first month of life), thrombocytopaenia 
(<150x109/L), leucopaenia (<5.0x109/L) and/or 
neutropaenia (<1.5x109/L)); intracranial calcifications, 
chorioretinitis, deafness (diagnosed by otoacoustic emis-
sions or auditory evoked potentials of the brainstem); 
antiviral therapy (drug and duration, if performed); 
length of hospital stay (if admitted) and immediate 
outcome; and family data (maternal age and job; number 
and age of siblings and their frequency of kindergarten 
or school) were also included in this questionnaire.
Cases (those with positive viruria for CMV in the first 
3 weeks of age) were classified as either symptomatic 
infection (also known as symptomatic disease) or asymp-
tomatic infection at diagnosis,9 based on the reported 
presence of any of the symptoms or signs listed above.
Maternal infection was considered primary if there was 
either reported positive IgM with low avidity IgG or docu-
mented IgG seroconversion during pregnancy, and clas-
sified as non-primary (meaning recurrent or reinfection) 
if there was reported documented positive IgG before 
pregnancy or positive IgM with high avidity CMV IgG in 
the early pregnancy samples.
The questionnaires at 6, 12 and 18 months and at 2, 3, 
4, 5 and 6 years of age consisted of questions regarding 
the clinical follow-up: physical examination, laboratory 
tests, cranial ultrasound scan findings, and audiological 
and ophthalmological assessment.
Cumulative birth prevalence rate was estimated with 
95% CI.
As a post-hoc analysis, the association between symp-
tomatic or asymptomatic presentation at diagnosis and 
type of maternal infection (primary or non-primary) was 
assessed. After assessing the heterogeneity of the possi-
bility for non-reported or for a reported unknown time 
of maternal infection if the offspring was symptomatic 
or asymptomatic at diagnosis, the odds for the type of 
maternal infection were estimated as ORs with 95% CI. 
OpenEpi was used for estimations.10
Patient involvement
Patients were not directly involved in the design of this 
study and the questionnaires were not sent to the parents.
results
Sixteen notifiers reported 40 cases of confirmed congen-
ital CMV infection. The median gestational age was 37 
weeks (29–40) and birth weight was 2912 g (790–4120 g). 
No twins were reported.
The reported cumulative birth prevalence in Portugal 
between 2006 and 2011 was 40 out of 610 263 live births 
or a prevalence rate of 6.6/105 live births (95% CI 4.81 
to 8.92).
Eighteen newborn infants (45%) were symptomatic 
and 22 (55%) were asymptomatic at birth. From the 
40 mothers, 21 (52.5%) were classified as having had 
primary infection and 10 as non-primary infection (25%); 
the mother’s previous serological status was not known 
in 9 cases (one woman with a positive IgM without IgG 
assessment during pregnancy was included is this group) 
(table 1). The odds for a non-reported or for a reported 
unknown time of maternal infection if the offspring was 
symptomatic at birth were 2.64 (95% CI 0.531 to 13.11; 
p=0.263).
From the 18 symptomatic newborn infants, 6 (33%) 
were born to mothers with primary infection and 9 
(50%) to mothers with secondary infection. The other 
three symptomatic patients were born from mothers 
whose serology was unknown (table 1). The odds for a 
reported non-primary maternal infection if the offspring 
was symptomatic at birth were 6.2 (OR 6.2; 95% CI 1.2 to 
32.27; p=0.033).
Follow-up information was received for 11 cases at 6 
months, for 8 cases at 1 year, for 6 cases at 3 years and 
for 2 cases after 4 years. Asymptomatic cases at birth 
remained symptomless at 6 months (6 children), 3 years 
(4 children) and 4 years (2 children). Regarding the 
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Table 1 Distribution of the 40 reported cases of congenital cytomegalovirus infection according to their clinical presentation 
at birth (symptomatic or asymptomatic) and reported maternal previous serological status
Primary infection Non-primary infection Unknown time of infection Total
Symptomatic at birth 6 (1) 7 (1) 5 (2) 18 (4)
Asymptomatic at birth 16 (3) 3 (1) 3 (2) 22 (6)
Total 22 (4) 10 (2) 8 (4) 40 (10)
In brackets are the number of children included in the follow-up. The odds for non-primary maternal infection were higher if the offspring was 
symptomatic at birth (OR 6.2; 95% CI 1.2 to 32.27; p=0. 0.033).
symptomatic cases, two were followed up for 6 months, 
one became asymptomatic, but the other one had severe 
neurological sequelae. The third child was asymptomatic 
at 1 year of age and the fourth had severe neurological 
impairment at 3 years of age (table 2). The two patients 
with the most severe sequelae at 6 months and 3 years 
were born, respectively, to mothers with primary and 
non-primary infection.
DIsCussIOn
This study reports the first national registry of congenital 
CMV infection in Portugal. Out of 610 263 live births, 
there were 40 new confirmed cases of congenital CMV 
infection reported between 2006 and 2011. Therefore, 
the reported cumulative birth prevalence rate was 6.6:105 
live births (95% CI 4.81 to 8.92). The British Paediatric 
Surveillance Unit was used to perform a similar study 
in 2001 and 2002 in the UK and Ireland.5 Eighty-six 
confirmed cases were registered in those 2 years, from 
circa 1.3 million live births. The estimated prevalence of 
congenital CMV in the two studies was similar and quite 
far from the expected 0.3%–0.5% (about 0.03%–0.05% 
for symptomatic cases) for the UK11 and 0.8%–1.5% 
(0.08%–0.15% for symptomatic cases) for Portugal.12 The 
estimates of both PPSU strongly suggest under-reporting. 
However, other surveillance reports do not seem to be 
more effective. The Canadian Paediatric Surveillance 
Program, between the years of 2005 and 2008, reported a 
birth prevalence of 4.5:105 live births,13 and a report from 
the five university hospitals in Finland detected 26 symp-
tomatic cases in 12 years.6 The National Congenital Cyto-
megalovirus Disease Registry of the USA detected 285 
cases in 4 years,4 in a country where more than 10 000 
cases/year would be expected if both symptomatic and 
asymptomatic infections were to be included. A recently 
published paper with data from the Australian Paedi-
atric Surveillance Unit also refers the under-reporting 
and under-recognition of congenital CMV despite the 
increasing use of antiviral therapy.14 Therefore, either 
the estimates based on clinical pathology data are over-
estimated or the available surveillance systems based on 
clinicians underestimate the number of congenital CMV 
infection.
Congenital CMV does not fulfil the conditions to be 
included in the list of notifiable infectious diseases, 
which means that these cases are not mandatorily 
registered. Therefore, alternative forms of surveillance 
are important for the knowledge of the epidemiology of 
this congenital infection, such as the universal neonatal 
screening. Of note, this screening has several important 
dilemmas, with the most frequent being that many true 
positives will be healthy babies without any complication 
or sequelae.15 Following examples of countries where a 
CMV surveillance system exists,4 5 12 the authors sought to 
use the PPSU as a source of national data on the occur-
rence of new cases and their evolution.8
Using the PPSU system as the primary source of data 
for this national registry, under-reporting and missed 
diagnosis must be taken into account, although the 
former is probably much more frequent. In fact, only 16 
notifiers registered the 40 cases, which means that the 
majority of the Portuguese paediatricians and neonatol-
ogists did not register any case. In addition, the system 
involves paediatricians who are included voluntarily in 
the mailing. This represents a bias given in Portugal many 
children are followed up by their family practitioner, the 
majority of whom are not participants of the surveillance 
system. Without a screening programme, some symptom-
atic cases, particularly those included in the group of the 
so-called ‘Mildly symptomatic congenital cytomegalo-
virus disease’, might also have been lost due to the fact 
that symptoms can be mild and transient9 and therefore 
easily missed.
On the other hand, the low return rate of the follow-up 
questionnaires was very disappointing and does not 
allow any generalisation. Those asymptomatic children 
at birth, from whom follow-up information was received, 
remained asymptomatic. Of note, none of them was 
followed up until 6 years of age. There is also a lack of 
information regarding the evolution of most symptom-
atic at birth cases. Of those where there is information, 
some seem to have come free of sequelae. Although the 
audiological evaluation was part of the initial evaluation 
(the Portuguese universal auditory screening programme 
started in 2007) and of the follow-up routine, all the noti-
fiers confirmed that it was always performed, but it was 
surprising that no case of deafness is referred. A possible 
explanation could be the late appearance of this sequela,1 
which together with the low number of children followed 
would decrease the probability of detecting cases of 
deafness.
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Table 2 Summary of the available information of all the cases of congenital cytomegalovirus infection reported (maternal 
information, symptoms and neuroimaging findings at birth and on follow-up)
Maternal infection At birth 6 months 1 year 2 years 3 years 4 years
1 Primary A A A – A A
2 Recurrent A A A – A A
3 Primary A A A – A –
4 Primary A A A – A –
5 Unknown A – – – – –
6 Unknown A A – – – –
7 Recurrent A A A A A –
8 Unknown IUGR, H A – – – –
9 Primary IUGR, VA CP, DCD, M, S – – – –
10 Unknown An, Cr, H, Hs, J, L, SBB, S, T A A – – –
11 Recurrent An, Ch, H, T, Hs CH, VSV AH At, D DS, DDFM, AMRI –
12 Unknown An, J, L, T – – – – –
13 Unknown A – – – – –
14 Recurrent J – – – – –
15 Primary AMRI – – – – –
16 Primary A – – – – –
17 Primary A – – – – –
18 Primary A – – – – –
19 Primary An, N, Vm – – – – –
20 Recurrent An, H, Hs, IC, SL, T – – – – –
21 Primary A – – – – –
22 Primary A – – – – –
23 Unknown A – – – – –
24 Primary A – – – – –
25 Primary A – – – – –
26 Primary A – – – – –
27 Recurrent An, Sp – – – – –
28 Primary A – – – – –
29 Primary IUGR – – – – –
30 Recurrent A – – – – –
31 Recurrent VSV – – – – –
32 Primary IC – – – – –
33 Recurrent IUGR, PCL – – – – –
34 Recurrent SL, L, T – – – – –
35 Recurrent SL, L, T, IUGR – – – – –
36 Recurrent IUGR – – – – –
37 Primary An, T, IC, D – – – – –
38 Primary A – – – – –
39 Primary A – – – – –
40 Primary A – – – – –
A, asymptomatic; AH, axial hypotonia; AMRI, abnormal MRI (unspecified); An, anaemia; At, ataxia; CH, cerebellar hypoplasia; CP, cerebral palsy; 
Ch, cholestasis; Cr, chorioretinitis; D, dystonia; DCD, diffuse cortical dysplasia; DDFM, delayed development of fine movements; DS, delayed 
speech; H, hepatitis; Hs, hepatosplenomegaly; IC, intracerebral calcifications; IUGR, intrauterine growth restriction; J, jaundice; L, leucopaenia; 
M, microcephaly; N, neutropaenia; PCL, periventricular cystic lesions; S, strabismus; SBB, subependymal bilateral bleeding; SL, sepsis-like; Sp, 
splenomegaly; T, thrombocytopaenia; VA, ventricular asymmetry; VSV, ventriculostriated vasculopathy; Vm, ventriculomegaly.
The study also suggests that symptomatic congenital 
CMV infection at birth is significantly higher for non-pri-
mary maternal infection (OR 6.2; 95% CI 1.2 to 32.27). 
In spite of the statistical significance of the association, 
the interpretation must take into account that data are 
based only on the reporting of newborns with confirmed 
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infection, as defined on the surveillance protocol (avail-
able at http://www. spp. pt/ conteudos/ default. asp? ID= 
143). There is the possibility of an identification bias due 
to the diagnostic process. It can be assumed that clini-
cians would proceed to confirm the diagnosis in case of 
prenatal suspicion or in newborns with symptoms or signs 
suggesting CMV infection. As such, there is potential for 
reporting bias given there would be less notification of 
asymptomatic infants from non-suspected pregnancies. A 
higher quality of the information on cases with prenatal 
suspicion of infection may also lead to reporting bias.
It is now widely accepted that mothers’ recurrent infec-
tions are responsible for symptomatic, sometimes severe, 
congenital infections in newborns. Some studies confirm 
that the majority of congenital infections result from the 
mother’s non-primary infection, particularly in coun-
tries with higher seroprevalence rates.16 However, even 
in countries with low seroprevalence rates, the impact 
of non-primary infections can be significant.6 Our data 
reinforce the relevance of maternal recurrent infection 
on the overall impact of symptomatic congenital CMV 
infections. This is a matter of major importance nowa-
days, since the discussion about the possible introduction 
of a CMV vaccine is very much focused on the observa-
tions that natural immunity is not completely protective 
against maternal reinfection and congenital transmis-
sion.17 However, there is evidence that vaccination is asso-
ciated with reduced transmission of CMV to the fetus in 
seronegative women, reason why some authors claim that 
in light of the substantial burden on society conferred by 
this infection, even a modest reduction in the occurrence 
is an important public health goal.18
COnClusIOns
Maternal recurrent infections can have a significant 
impact on the occurrence of symptomatic infections 
in newborns. Similar to studies in other countries, the 
surveillance of congenital CMV infection in Portugal 
revealed the problem of under-reporting of cases. New 
strategies are necessary to improve the registration of this 
congenital infection by clinicians in order to improve 
knowledge of the epidemiology in each country.
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